We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead Sciences has reached a $33 million settlement with a Florida clinic accused of fraudulently applying to the company’s patient assistance program via homeless people and those in low-wage jobs in order to get access to Gilead’s pricey human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) drugs for free, then selling them on the black market. Read More
For circumstances when drugmakers feel labeling alone isn’t enough to ensure safe selection and use, the FDA is proposing a rule that would expand the pool of nonprescription drugs with “self-selection systems” that would identify the appropriate patients and guide them in taking the medicines safely. Read More
The FDA has released its Spring 2022 regulatory agenda, pushing back the timing of several previously announced proposed and final rules, and signaling its intention to issue a proposed rule on compounded drug products by the end of the year. Read More
The FDA should be allowed to reform the citizen petition process and change how complex generic drugs are approved, the Brookings Institution and the University of Southern California (USC) propose in a recently published paper. Read More
Molecure said it is considering going back to its original plan, which was to develop OATD-01 for treatment of the inflammatory disease sarcoidosis. Read More
Study investigators said it is “expected there will be limited [Aduhelm] prescription and usage in routine clinical practice making the study not feasible for enrollment.” Read More
The European Medicines Agency (EMA)’s human medicines committee endorsed nine new drugs during its June meeting, including Valneva’s adjuvanted COVID-19 vaccine for use in people age 18 to 50 years. Read More
Under a new five-year action plan for accelerating the development of treatments for rare neurodegenerative diseases, the FDA will focus on incorporating new technologies and innovative trial approaches beginning with the study of amyotrophic lateral sclerosis (ALS). Read More
The FDA has expanded the scope of its 2013 drug manufacturing guidance on penicillin cross-contamination to cover compounds containing a non-penicillin beta-lactam ring, a chemical structure essential for antibacterial activity. Read More
Sarepta Therapeutics has been hit with an FDA clinical hold on its trial of SRP-5051 (vesleteplirsen) for the treatment of Duchenne muscular dystrophy after a trial participant experienced a serious adverse event (SAE) that could have been life-threatening. Read More